Richard H. De Boer

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

Alison Stopeck, Allan Lipton, Jean-Jacques Body et al. · Journal of Clinical Oncology · 2010 · 1.6K citations

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

Richard H. De Boer, Óscar Arrieta, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2011 · 289 citations

Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial

J.F.R. Robertson, Jean-­Marc Ferrero, Hugues Bourgeois et al. · The Lancet Oncology · 2013 · 162 citations

Breast Oncology, Medicine, Clinical Trials +12

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

Jean-Jacques Body, Henry G. Bone, Richard H. De Boer et al. · European Journal of Cancer · 2015 · 144 citations · Full text

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer

Guy Jérusalem, Richard H. De Boer, Sara A. Hurvitz et al. · JAMA Oncology · 2018 · 108 citations · Full text